Grace O’Connor — Health & Science Editor

Antiphospholipid syndrome (APS) is an acquired autoimmune disorder causing recurrent arterial or venous thrombosis and pregnancy morbidity. Managing APS is a balancing act between preventing life-threatening clots and avoiding major bleeding. For years, the gold standard has been long-term anticoagulation using vitamin K antagonists, typically maintained at an international normalised ratio of 2.0–3.0. However, the … Read more

Recent research from the University of Copenhagen indicates that the human brain is biologically wired to defend a higher body weight once it has been gained. This biological “memory” triggers hunger hormones and reduces energy expenditure to prevent weight loss, making long-term weight maintenance a physiological challenge rather than a failure of willpower. For years, … Read more

Researchers from UCL have found that midlife multimorbidity in England and Wales is linked to neighborhood deprivation and selective migration rather than coastal living itself. A study published in BMJ Public Health reveals that people moving out of coastal areas before age 42 typically have better health than those who stay or move in. Living … Read more

Venovenous extracorporeal membrane oxygenation (VV-ECMO) may serve as a bridge to recovery for a carefully selected group of patients experiencing severe acute respiratory failure due to treatable hematologic malignancies, according to a case report published in Cureus. VV-ECMO May Bridge Recovery for Patients With Hematologic Malignancies While VV-ECMO has historically been linked to poor outcomes … Read more

New clinical data and modeling indicate that long-acting HIV prevention and treatment, specifically lenacapavir and cabotegravir, are significantly reducing infection rates. The shift from daily pills to long-acting injectables is fundamentally changing the math of HIV prevention. For years, the primary barrier to PrEP (pre-exposure prophylaxis) success has been adherence; if a patient misses doses, … Read more

Researchers have re-engineered the psychedelic compound quipazine into a new molecule, VCU-1012, that maintains therapeutic serotonin 2A receptor binding in mice while eliminating the serotonin 3 receptor activation responsible for nausea. The development arrives as a Phase 3 trial for an LSD-derived depression therapy also reports positive topline results. The race to separate the therapeutic … Read more